Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721167 | 1.00 | DPP4 (0.48) | DPP4DPP7ALDH1A1MAPTHTT | |
| SCHEMBL902826 | 1.00 | DPP4 (0.48) | DPP4DPP7ALDH1A1MAPTHTT | |
| SCHEMBL19186660 | 0.87 | DPP4 (0.48) | DPP4DPP7ALDH1A1MAPTHTT | |
| SCHEMBL7902907 | 0.87 | DPP4 (0.48) | DPP4DPP7ALDH1A1MAPTHTT | |
| SCHEMBL12027403 | 0.84 | DPP4 (0.40) | DPP4DPP7 | |
| SCHEMBL28931518 | 0.84 | DPP4 (0.42) | DPP4DPP7MAPT | |
| SCHEMBL8310385 | 0.83 | DPP4 (0.44) | DPP4DPP7ALDH1A1MAPTHTT | |
| SCHEMBL9985996 | 0.83 | DPP4 (0.48) | DPP4DPP7 | |
| SCHEMBL9985994 | 0.83 | DPP4 (0.48) | DPP4DPP7 | |
| SCHEMBL743991 | 0.83 | DPP4 (0.53) | DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | claimed |
| US-20090123983-A1 | Processes for preparing an intermediate of sitagliptin via enzymatic reduction | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-14 | — | — | US | claimed |
| WO-2009045507-A2 | PROCESSES FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-09 | — | — | WO | claimed |
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | LEE PHARMA LIMITED (IN) | 2019-10-22 | — | — | US | disclosed |
| EP-2694466-B1 | PREPARATION OF SITAGLIPTIN INTERMEDIATES | LEK PHARMACEUTICALS (SI) | 2018-10-24 | — | — | EP | disclosed |
| US-20180265513-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | LEE PHARMA LIMITED (IN) | 2018-09-20 | — | — | US | disclosed |
| EP-2802554-B1 | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS (SI) | 2018-04-25 | — | — | EP | disclosed |
| EP-2802554-B1 | PREPARATION OF OPTICALLY PURE ß-AMINO ACID TYPE ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS (SI) | 2018-04-25 | — | — | EP | disclosed |
| EP-3242879-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | Lee Pharma Ltd. (IN) | 2017-11-15 | — | — | EP | disclosed |
| US-9409912-B2 | Process for the preparation of sitagliptin phosphate | CADILA HEALTHCARE LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| WO-2016110750-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | LEE PHARMA LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| EP-2615080-A1 | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof | LEK Pharmaceuticals d.d. (SI) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012136383-A2 | PREPARATION OF SITAGLIPTIN INTERMEDIATES | LEK PHARMACEUTICALS D.D. (SI) | 2012-10-11 | — | — | WO | disclosed |
| EP-2508506-A1 | Preparation of sitagliptin intermediates | LEK Pharmaceuticals d.d. (SI) | 2012-10-10 | — | — | EP | disclosed |
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
| WO-2009045507-A3 | PROCESSES FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC REDUCTION | TEVA PHARMA (IL) | 2009-06-04 | — | — | WO | disclosed |
| US-20090123983-A1 | Processes for preparing an intermediate of sitagliptin via enzymatic reduction | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-14 | — | — | US | disclosed |
| US-20090123983-A1 | Processes for preparing an intermediate of sitagliptin via enzymatic reduction | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-14 | — | — | US | disclosed |
| WO-2009045507-A2 | PROCESSES FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045507-A2 | PROCESSES FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123983-A1 | Processes for preparing an intermediate of sitagliptin via enzymatic reduction | DPP4, DPP3, SI | DPP4 1/4885DPP7 5/4885ALDH1A1 502/4885 |
| US-20180265513-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | DPP4, DPP7, DPP9 | DPP4 1/4885DPP7 2/4885ALDH1A1 609/4885 |
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885ALDH1A1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.